evaluable

The researchers considered 31 of the 43 patients to be evaluable for response.

Among 175 evaluable patients, only one patient met the criteria for response.

Ten patients in each study completed at least 8 weeks of treatment and therefore were considered evaluable for response.

The characteristics of the evaluable patients are listed in Table 1.

Response was assessed after each 8-week treatment cycle, and were evaluable for 236 of 296 patients.

The trial was conducted with one interim analysis after nine evaluable patients.

Four of the six evaluable stage I patients were treated with cyclophosphamide.

We included all evaluable index patients diagnosed between November 1991 and June 2002.

Fifty five patients had dietary intake of iron assessed and data from 47 were evaluable.

Efficacy of Therapy Twenty-eight patients are evaluable for treatment response.

In the cytogenetic study only 3 metaphases were evaluable, 2 of them being normal and the other 3n.

The study randomized 205 to treatment, however, only 178 patients were evaluable by protocol at the end of an 8-week treatment period.

Among the evaluable patients, one individual who had ovarian cancer had a complete response that lasted more than 2 months.

Of 62 evaluable patients, 38 patients developed complete cytogenetic remission.

An example of a highly evaluable attribute is SAT score.

If a statement's truth value is ultimately tied up in some evaluable fact about the world, that statement is "grounded".

Slice Sampling requires that the distribution to be sampled be evaluable.

Cytogenetic analysis of the bone marrow showed 3n hyperdiploidy (15 evaluable metaphases).

Compare SAT score to a poorly evaluable attribute, such as number of hours spent doing homework.

All evaluable patients were shown to have maintained the pre-specified threshold for asparaginase activity at 48 or 72 hours after dosing.

Because the distribution of scores on this attribute is relatively well known it is a highly evaluable attribute.

Of the evaluable population, approximately 18% were treated with high-dose therapy and stem cell transplantation in first remission.

Statistical Methods This study was planned to recruit 50 evaluable patients, allowing us to estimate objective tumor response to within +/- 15% with 95% confidence.

Approximately 91% of the evaluable patients remained free of detectable cancer during follow-up; 9% showed signs of progressive disease.

No complete responses or partial responses were observed among 50 evaluable patients who were treated with Cartilade for at least 6 weeks.